FPT-CORPORATION
16.4.2024 08:23:31 CEST | Business Wire | Press release
As part of its ongoing commitment to the highest standards of sustainable development, FPT Corporation (FPT) has published its ESG report and prioritized ESG as a key aspect of its 2024 development strategy. The report highlights FPT’s achievement of 87% positive employee feedback, certified by Great Place to Work® - a significantly higher rating than a typical global company’s average of 53%. The Corporation is also certified among Vietnam's Top 10 Best Large-Scale Workplaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415745348/en/
Happy Run race is one of FPT’s social responsibility activities (Photo: Business Wire)
“In 2023, I described FPT as a joyful sanctuary. I delineated the concept wherein FPT assumed the role of building a happier future for shareholders, customers, and employees. This depiction has begun to manifest itself into reality,” said FPT Chairman Dr. Truong Gia Binh.
FPT’s ESG commitment is reflected in four key areas: Work Environment, Environmental Sustainability, Social Responsibility, and Excellent Governance, with actions taking references from Global Reporting Initiative (GRI) Standards and 17 Sustainable Development Goals of the United Nations.
Building on the core values of "Respect - Innovation - Cohesion - Equality - Exemplarity - Lucidity," FPT is committed to creating a happy, diverse, and inclusive workplace. The Corporation has employees from 73 nationalities, with women representing 37.4% of the total workforce and 36.1% of managerial roles.
In 2023, the number of foreign employees at FPT increased by 67% year-on-year to 2,925, including senior-level members from such companies as Airbus, SCSK, Tata Consultancy Services, and HCL. FPT also recorded a decade-low turnover rate of 10.3% and a 13.6% increase in the total workforce compared to 2022. “We prioritize building a cohesive, family-like atmosphere where leaders and employees regard one another as family. In times of adversity, we stand together and never leave anyone behind,” FPT Chairman Dr. Truong Gia Binh added.
Social responsibility forms an integral part of FPT's culture. In 2023, FPT donated VND 205.2 billion (approximately $8.2 million) to social responsibility activities, benefiting over 83,753 people in Vietnam. The company's first global Happy Run race attracted 191,000 participants, raising VND 3.6 billion (approximately $145,000) to build schools in remote areas. Hope School - FPT’s initiative to support children orphaned by COVID-19 - has continued to ensure a safe and comprehensive learning environment for 230 students from 41 provinces, with a new construction set to be completed in 2024.
The Corporation also demonstrates its strong commitment to environmental conservation and the ambitious goal of becoming the pioneering company in Vietnam to achieve Net Zero emissions by 2040. FPT has been applying various measures to minimize environmental impact by reducing energy consumption and greenhouse gas emissions, such as monitoring 100% of energy usage data and replacing 100% of office waste bags with recyclable materials, while ensuring all employees receive annual training on environmental protection policy.
Regarding corporate governance, FPT pledges to build and maintain a governance framework including charter, regulations, process handbooks, and regulatory documents across the Corporation to ensure a professional, effective and disciplined governance system from the Corporation to its subsidiaries.
Vertical functional management and centralized data management serve as the "backbone" of FPT's efforts to optimize its management and operations, as well as fostering sustainable growth. The Corporation also conducted internal digital transformation projects, with 42 being implemented in 2023 to ensure cost savings, optimize operations, and improve experience for both employees and customers.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com.vn/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415745348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
